Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XBIOW

Xenetic Biosciences (XBIOW) Stock Price, News & Analysis

Xenetic Biosciences logo

About Xenetic Biosciences Stock (NASDAQ:XBIOW)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$16.70
$20.50
50-Day Range
$12.01
$22.94
52-Week Range
$1.02
$20.50
Volume
3,300 shs
Average Volume
800 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Remove Ads
Receive XBIOW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIOW Stock News Headlines

Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Xenetic partner PeriNess enters clinical study agreement for XBIO-015
Xenetic partner PeriNess enters clinical study agreement for XBIO-015
H.C. Wainwright Remains a Hold on Xenetic Biosciences (XBIO)
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XBIOW
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.44 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best Stocks to Own: Spring 2025 Cover

Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.

Get This Free Report

This page (NASDAQ:XBIOW) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners